Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    5
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 712,237 L.L
J01DC10 CEFPROZ 250 G Cefprozil - 250mg/5ml 250mg/5ml Powder for suspension 1,343,843 L.L
J01DD02 CEFTAZIDIME PANPHARMA G Ceftazidime (pentahydrate) - 1g 1g Injectable powder for solution 3,300,477 L.L
J01DD07 CEFIZOX B Ceftizoxime (sodium) - 1g 1g Injectable powder for solution 788,836 L.L
J01DD04 CEFTRIAXONE PANPHARMA G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 8,005,714 L.L
J01DD04 CEFAXONE G Ceftriaxone - 1g 1g Injectable powder 403,153 L.L
J01DD04 CEFAXONE IM/IV G Ceftriaxone - 1g 1g Injectable lyophilised powder for solution 3,628,375 L.L
J01DD04 CEFAXONE IV G Ceftriaxone - 1g 1g Injectable lyophilised powder for solution+diluent 403,153 L.L
J01DC02 CEFUZIME G Cefuroxime (axetil) - 500mg 500mg Tablet, film coated 490,503 L.L
J01DC02 CEFORA G Cefuroxime (axetil) - 500mg 500mg Tablet 703,918 L.L
J01DC02 CEFUZIME G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 147,823 L.L
J01DC02 CEFUMAX G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 159,917 L.L
J01DC02 CEFUROXIME – PANPHARMAPOUDRE POUR SOLUTION INJ. IM/IV G Cefuroxime (sodium) - 750mg 750mg Injectable dry powder 3,922,676 L.L
J01DC02 CEFUROXIME – PANPHARMAPOUDRE POUR SOLUTION INJ. IM/IV G Cefuroxime (sodium) - 750mg 750mg Injectable powder for solution 1,651,582 L.L
J01DC02 CEFUREX G Cefuroxime - 500mg 500mg Tablet 490,503 L.L
M01AH01 CELECOXIB BIOGARAN G Celecoxib - 100mg 100mg Capsule 318,491 L.L
M01AH01 CELEBREX B Celecoxib - 200mg 200mg Capsule 1,126,140 L.L
M01AH01 CELECOXIB ARROW LAB G Celecoxib - 200mg 200mg Capsule 561,726 L.L
M01AH01 CELECOXIB BIOGARAN G Celecoxib - 200mg 200mg Capsule 638,325 L.L
N07X CEREBROLYSIN G Cerebrolysin - 215.2mg/ml 215.2mg/ml Injectable concentrated solution 2,303,346 L.L
N07X CEREBROLYSIN G Cerebrolysin - 215.2mg/ml 215.2mg/ml Injectable concentrated solution 3,886,393 L.L
R06AE07 CETRAK G Cetirizine (dihydrochloride) - 10mg 10mg Tablet 147,823 L.L
R06AE07 CETALLERG G Cetirizine (dihydrochloride) - 10mg 10mg Tablet, film coated 180,075 L.L
R06AE07 CETIMED G Cetirizine (dihydrochloride) - 10mg 10mg Tablet, scored 360,918 L.L
R06AE07 CETIMED G Cetirizine (dihydrochloride) - 5mg/5ml 5mg/5ml Solution 415,951 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 3,420,079 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 3,420,079 L.L
J01BA01 CHLORAMPHENICOL PALMITATE G Chloramphenicol (palmitate) - 125mg/5ml 125mg/5ml Suspension 159,981 L.L
    5
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025